Summary of Use during Lactation

No information is available on the clinical use of avapritinib during breastfeeding. Because avapritinib is 98.8% bound to plasma proteins, the amounts in milk are likely to be low. However, the manufacturer recommends avoiding breastfeeding during therapy and for 2 weeks following the final dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Avapritinib

CAS Registry Number

1703793-34-3

Drug Class

Breast Feeding

Lactation

Antineoplastic Agents

Enzyme Inhibitors

Protein Kinase Inhibitors

Signal Transduction Inhibitors

Tyrosine Kinase Inhibitors